CRBU Quote, Financials, Valuation and Earnings

Bioage Labs has a net margin of -1713.64% compared to Caribou Biosciences's net margin of --. Caribou Biosciences's return on equity of -43.52% beat Bioage Labs's return on equity of --.

Caribou Biosciences has a consensus price target of $13.25, signalling upside risk potential of 766.01%. On the other hand Bioage Labs has an analysts' consensus of $6.33 which suggests that it could grow by 23.22%. Given that Caribou Biosciences has higher upside potential than Bioage Labs, analysts believe Caribou Biosciences is more attractive than Bioage Labs.

Caribou Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bioage Labs has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Caribou Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bioage Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences pays -- of its earnings as a dividend. Bioage Labs pays out -- of its earnings as a dividend.

Caribou Biosciences quarterly revenues are $2M, which are larger than Bioage Labs quarterly revenues of --. Caribou Biosciences's net income of -$34.7M is lower than Bioage Labs's net income of -$13.6M. Notably, Caribou Biosciences's price-to-earnings ratio is -- while Bioage Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences is 11.96x versus -- for Bioage Labs. Usually stocks with elevated PS ratios are considered overvalued.

Codexis has a net margin of -1713.64% compared to Caribou Biosciences's net margin of -160.84%. Caribou Biosciences's return on equity of -43.52% beat Codexis's return on equity of -79.15%.

Caribou Biosciences has a consensus price target of $13.25, signalling upside risk potential of 766.01%. On the other hand Codexis has an analysts' consensus of $7.50 which suggests that it could grow by 50%. Given that Caribou Biosciences has higher upside potential than Codexis, analysts believe Caribou Biosciences is more attractive than Codexis.

Caribou Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Codexis has a beta of 2.131, suggesting its more volatile than the S&P 500 by 113.072%.

Caribou Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Codexis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences pays -- of its earnings as a dividend. Codexis pays out -- of its earnings as a dividend.

Caribou Biosciences quarterly revenues are $2M, which are smaller than Codexis quarterly revenues of $12.8M. Caribou Biosciences's net income of -$34.7M is lower than Codexis's net income of -$20.6M. Notably, Caribou Biosciences's price-to-earnings ratio is -- while Codexis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences is 11.96x versus 5.47x for Codexis. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -1713.64% compared to Caribou Biosciences's net margin of --. Caribou Biosciences's return on equity of -43.52% beat CEL-SCI's return on equity of --.

Caribou Biosciences has a consensus price target of $13.25, signalling upside risk potential of 766.01%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1820.85%. Given that CEL-SCI has higher upside potential than Caribou Biosciences, analysts believe CEL-SCI is more attractive than Caribou Biosciences.

Caribou Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Caribou Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Caribou Biosciences quarterly revenues are $2M, which are larger than CEL-SCI quarterly revenues of --. Caribou Biosciences's net income of -$34.7M is lower than CEL-SCI's net income of -$6.9M. Notably, Caribou Biosciences's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences is 11.96x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -1713.64% compared to Caribou Biosciences's net margin of -416.75%. Caribou Biosciences's return on equity of -43.52% beat IGC Pharma's return on equity of -137.43%.

Caribou Biosciences has a consensus price target of $13.25, signalling upside risk potential of 766.01%. On the other hand IGC Pharma has an analysts' consensus of $4.00 which suggests that it could grow by 1076.82%. Given that IGC Pharma has higher upside potential than Caribou Biosciences, analysts believe IGC Pharma is more attractive than Caribou Biosciences.

Caribou Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

Caribou Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Caribou Biosciences quarterly revenues are $2M, which are larger than IGC Pharma quarterly revenues of $412K. Caribou Biosciences's net income of -$34.7M is lower than IGC Pharma's net income of -$1.7M. Notably, Caribou Biosciences's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences is 11.96x versus 19.88x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.